These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 11169005

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
    Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y.
    Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients.
    Matsuo K, Nakamoto M, Yasunaga C, Goya T, Sugimachi K.
    Kidney Int; 1997 Sep; 52(3):832-8. PubMed ID: 9291206
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Chronic intestinal pseudo-obstruction due to dialysis-related amyloid deposition in the propria muscularis in a hemodialysis patient.
    Kanai H, Kashiwagi M, Hirakata H, Nagashima A, Tada S, Yao T, Nakamoto M, Nakamura S, Fujishima M.
    Clin Nephrol; 2000 May; 53(5):394-9. PubMed ID: 11305814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Transforming growth factor-beta is involved in the pathogenesis of dialysis-related amyloidosis.
    Matsuo K, Ikizler TA, Hoover RL, Nakamoto M, Yasunaga C, Pupim LB, Hakim RM.
    Kidney Int; 2000 Feb; 57(2):697-708. PubMed ID: 10652049
    [Abstract] [Full Text] [Related]

  • 14. Reduction of circulating beta2-microglobulin level for the treatment of dialysis-related amyloidosis.
    Kazama JJ, Maruyama H, Gejyo F.
    Nephrol Dial Transplant; 2001 Feb; 16 Suppl 4():31-5. PubMed ID: 11402095
    [Abstract] [Full Text] [Related]

  • 15. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis.
    García-García M, Argilés, Gouin-Charnet A, Durfort M, García-Valero J, Mourad G.
    Kidney Int; 1999 Mar; 55(3):899-906. PubMed ID: 10027926
    [Abstract] [Full Text] [Related]

  • 16. Dialysis-related amyloidosis: pathogenesis focusing on AGE modification.
    Niwa T.
    Semin Dial; 2001 Mar; 14(2):123-6. PubMed ID: 11264780
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fatal cardiac beta2-microglobulin amyloidosis in patients on long-term hemodialysis.
    Kawano M, Muramoto H, Yamada M, Minamoto M, Araki H, Koni I, Mabuchi H, Nonomura A.
    Am J Kidney Dis; 1998 Mar; 31(3):E4. PubMed ID: 10074578
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.